Biocompatibility should not be viewed as a final regulatory hurdle-it should be a strategic consideration integrated throughout product development. By incorporating biocompatibility planning from the onset, manufacturers can identify potential risks earlier, make informed material and design decisions, and reduce the likelihood of costly delays during the safety testing process.

During this webinar, we will discuss:

• How a proactive, risk-based approach to biocompatibility supports successful regulatory submissions
• How early collaboration enables smarter planning, optimizes testing strategies, and aligns with current ISO 10993 expectations
  
• Insights into building your biocompatibility testing plan
  
• Ways to minimize risk, improve efficiency and accelerate your path to market
  

	Patricia (Trish) Curry, Ph.D. Senior Scientific Advisor, Biocompatibility & Chemistry Eurofins Medical Device Services
As Senior Scientific Advisor, Trish Curry serves as a subject matter expert in biocompatibility & chemistry testing services supporting clients in the development of comprehensive testing plans. She has more than 11 years of medical device safety testing experience, with expertise in ISO 10993 guidelines and testing strategy development for international regulatory submissions. Prior to joining Eurofins, she served in a Business Development Director role at Labcorp in the Preclinical Medical Device unit, held positions at Toxikon Corporation (Business Development & Technical Advisor), for Biocompatibility, Efficacy & Surgical Research, Analytical Chemistry/E&L, and Microbiology departments. Trish serves on several U.S. working groups for the ISO 10993 series of standards, including ISO 10993-9 (Framework for identification and quantification of potential degradation products), ISO 10993-4 (Selection of tests for interactions with blood), ISO 10993-6 (Tests for local effects after implantation, ISO 10993-11 (Tests for systemic toxicity) BE-WG07-Systemic toxicity, USP-NF<151> BE-WG16-Pyrogenicity, and ISO 22442 (Medical devices utilizing animal tissues and their derivatives). She earned her PhD from The University of Tennessee Knoxville where she also conducted research on hemocompatibility screenings of medical device coatings.
	Todd Stark, Ph.D. Regional Sales Manager Eurofins Medical Device Services
As Regional Sales Manager for Eurofins Medical Device Services, Todd Stark, Ph.D., works with clients to identify and utilize the full breadth of testing services offered by Eurofins. Dr. Stark has over 25 years of experience with contract services in both the pharma and medical device industries. Todd holds a Ph.D. in Organic Chemistry from UCLA.